Clinical Scorecard: Impact of Prior Glucagon-Like Peptide 1 Agonist Use on Cardiovascular Events and Mortality in Diabetic Patients with Multiple Myeloma Treated with Proteasome Inhibitors

At a Glance

Key Highlights

• GLP1 agonist use prior to proteasome inhibitor therapy is associated with a 33% reduction in major adverse cardiovascular events (MACE).
• GLP1 agonists reduce heart failure risk by approximately 43% and all-cause mortality by 44% in this patient population.
• No increased risk of adverse events such as pancreatitis, biliary disease, bowel obstruction, or gastroparesis was observed with GLP1 agonist use.

Guideline-Based Recommendations

Diagnosis

• Identify patients with multiple myeloma and Type 2 diabetes mellitus initiating proteasome inhibitor therapy.
• Exclude patients with prior myocardial infarction or heart failure to focus on primary cardiovascular prevention.

Management

• Consider prescribing GLP1 agonists within one year prior to proteasome inhibitor initiation to reduce cardiovascular events and mortality.
• Continue standard diabetes management alongside proteasome inhibitor therapy.

Monitoring & Follow-up

• Monitor for incident cardiovascular events including heart failure, myocardial infarction, atrial fibrillation, and ischemic stroke within one year of proteasome inhibitor initiation.
• Surveillance for serious adverse events related to GLP1 agonists such as pancreatitis and gastrointestinal complications.

Risks

• GLP1 agonist use was not associated with increased adverse events in this population.
• Proteasome inhibitors carry inherent cardiovascular risks requiring careful cardiovascular monitoring.

Patient & Prescribing Data

Patients with multiple myeloma and Type 2 diabetes mellitus receiving proteasome inhibitors

GLP1 agonist therapy prior to proteasome inhibitor treatment is linked to significant reductions in MACE, heart failure, and mortality without increased adverse events.

Clinical Best Practices

• Use propensity score matching to balance baseline characteristics when evaluating treatment effects in observational studies.
• Exclude patients with prior cardiovascular events to assess primary prevention benefits of GLP1 agonists.
• Incorporate GLP1 agonists as part of comprehensive cardiovascular risk reduction strategies in diabetic MM patients on proteasome inhibitors.

References

• TriNetX Network